At the 2026 ACC, researchers presented a meta-analysis of three trials (1,264 patients) assessing baxdrostat’s blood pressure and safety effects in uncontrolled hypertension. Geared towards low-income patients with uncontrolled hypertension, a multifaceted, team-based implementation strategy for blood pressure (BP) management led to a mean reduction of 15.5 mm Hg in ... A multifaceted initiative applied at the clinic, physician and patient levels improved blood pressure among low-income patients with uncontrolled hypertension, researchers reported.The intervention ...
A multifaceted, team-based care strategy significantly reduced blood pressure (BP) in low-income patients with uncontrolled hypertension, according to a study led by researchers at UT Southwestern ... MarketWatch: Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC Renal & Urology News: Lorundrostat Beneficial for Patients With Uncontrolled, Resistant Hypertension News Medical: Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a ... Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension
